ArchiMed takes biopharma firm Esperion Therapeutics private for $1.1bn

Esperion focuses on bringing cardiometabolic and rare/orphan disease therapies to market.

14 July 2026•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.